Troponin -T as a prognostic and diagnostic marker for myocardial infarction
1 DG Vaishnav College, Arumbakkam, Chennai, India - 600 105
2 Bharath institute of higher education and research, selaiyur, Chennai, India – 600 073
Research Article
GSC Biological and Pharmaceutical Sciences, 2021, 14(01), 095-100.
Article DOI: 10.30574/gscbps.2021.14.1.0005
Publication history:
Received on 02 January 2021; revised on 09 January 2021; accepted on 10 January 2021
Abstract:
Over the past decade, there has been a progressive evolution of cardiac marker testing in patients with acute coronary syndromes. Myocardial infarction (MI) is the leading cause of death in the developed world. Biomarkers have an vital role in analysis, risk stratification, administrative running and medical assessment making in the setting of patients presenting with signs and symptoms of MI. Cardiac troponin (cTn) rose to prominence during the 1990s and has evolved to be the cornerstone for diagnosis of MI. Cardiac troponins are released from myocytes following myocardial damage and loss of membrane integrity. Troponin T are member of a group of cardiac regulatory proteins which function to regulate the calcium mediated interaction of muscle filaments actin and myosin resulting in contraction and relaxation of striated muscle. New algorithms integrating Brain natriuretic peptide (BNP), NT-proBNP, and more sensitive cTn assays footing potential for more rapid diagnosis of MI, allowing for appropriate management steps to be initiated and more efficient and effective utilization of healthcare resources.
Keywords:
Myocardial infarction; Biomarkers; Troponin; Brain natriuretic peptide; Cardiac troponin
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
